Clinical Advisory Board

Savara Pharmaceuticals / About Savara / Clinical Advisory Board

Elliott C. Dasenbrook

MD MHS

Dr. Dasenbrook is Assistant Professor of Medicine and Associate Director of the Adult Cystic Fibrosis Program at Case Western Reserve University (CWRU) School of Medicine. He is a leading researcher on the effects of MRSA in cystic fibrosis patients. Dr. Dasenbrook co-authored a ground-breaking study in 2010 that showed the impact on survival is a life span that is a median 6.2 years shorter in CF patients with MRSA than those without.

Patrick Flume

MD

Dr. Flume is a Professor of Medicine and Pediatrics at the Medical University of South Carolina. He oversees a rapidly growing Cystic Fibrosis Center, including the largest adult CF program in South Carolina. He is recognized by the national and international CF community having served on the CF Foundation Center Committee, the Adult Care Consensus Committee, and the Advisory Task Force on Adult Issues, the Professional Education Committee, and as Founding Co-chair of the CF Foundation Pulmonary Practice Guidelines Committee.

Taneli Jouhikainen

COO

Dr. Jouhikainen (MD, PhD, MBA) is one of the founders of Savara and serves as Chief Operating Officer. During his career as a veteran medical executive, Dr. Jouhikainen has held executive positions with several companies including Interim CEO and Senior Vice President of Product Development at Akela Pharma Inc., President and CEO at Focus Inhalation, Chairman of the Board at Spectrum Medical Sciences, and Director of Clinical Research at Leiras/Schering AG.

Michael Konstan

MD

Dr. Konstan is the Chairman of the Department of Pediatrics of Case Western Reserve University (CWRU) School of Medicine. In addition, he is the director of The LeRoy W. Matthews Cystic Fibrosis Center at Rainbow Babies and Children’s Hospital. Dr. Konstan’s academic career has focused on developing new therapies for the lung disease of cystic fibrosis (CF), with a special interest in anti-inflammatory therapies and clinical trial design. He has led numerous national and international CF trials of potentially new therapies for cystic fibrosis, and is regarded as a national and international expert in this disease.

Felix Ratjen

MD, FRCP(C)

Dr. Ratjen is the Division Chief of Paediatric Respiratory Medicine at The Hospital for Sick Children, Professor of Paediatrics at The University of Toronto, and Senior Scientist at the Research Institute in the Department of Physiology and Experimental Medicine. He is Co-leader of the Cystic Fibrosis center at SickKids and Medical Director of the Clinical Research Unit. Dr. Ratjen has conducted multiple clinical trials addressing cystic fibrosis lung disease including new therapeutic strategies, treatment of airway infections, airway inflammation and other important aspects of the disease.

Grant Waterer

MBBS PhD MBA FRACP FCCP

Dr Waterer is a respiratory physician at Royal Perth Hospital and is a Professor of Medicine at the University of Western Australia and Professor of Medicine at Northwestern University, Chicago.  He is currently the Chair of the American Thoracic Society and Infectious Diseases Society of America Community Acquired Pneumonia Guidelines and a panel member of the ATS/IDSA HAP/VAP guidelines.  He has over 150 peer reviewed publication, more than 60 invited international presentations and is on the Editorial Board of 8 journals including the American Journal of Respiratory and Critical Care Medicine, Chest and the European Respiratory Journal.  In addition to his academic qualifications he has an MBA, is currently a board member of the North Metropolitan Area Health Service and a Medical Director at Royal Perth Hospital.

Back to Top